Gary Brecka dropped a bombshell that most doctors still won't tell you: up to 40% of people have a genetic variant that makes folic acid — the form in almost every supplement and fortified food — nearly useless. Some of those people are actively being harmed by it.
This isn't fringe science. The MTHFR gene and its variants are among the most studied genetic polymorphisms in medicine. The problem is that conventional medicine hasn't translated that research into routine practice. Brecka has, and it's the foundation of everything he does.
The core of Brecka's philosophy: You can take every supplement in the world, eat perfectly, and exercise daily — and if your methylation cycle is broken, you'll still feel stuck. Fix the upstream problem first.
Methylation is one of the most important chemical processes in your body. It happens billions of times per second. It controls: how your genes are expressed, how you process toxins, how you make neurotransmitters (dopamine, serotonin), how you regulate inflammation, and how you metabolize hormones including estrogen.
For methylation to work, your body needs folate — specifically, the active form called 5-methyltetrahydrofolate (5-MTHF). The MTHFR enzyme converts dietary folate and folic acid supplements into this active form. Here's the problem: if your MTHFR gene is mutated, that conversion is severely impaired.
Variants range from mild (C677T heterozygous, ~30% reduced efficiency) to severe (C677T + A1298C compound heterozygous, 70-80% reduced efficiency). People with severe variants who take folic acid may be flooding their system with a form their body can't use — and blocking the little active folate they do make.
The fix is simple and cheap: switch from folic acid to L-methylfolate (5-MTHF). It bypasses the MTHFR conversion entirely. Your body gets the active form directly.
The methylation cycle is a one-carbon metabolic pathway. The MTHFR enzyme (methylenetetrahydrofolate reductase) converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which donates its methyl group to homocysteine via methionine synthase, regenerating methionine. Methionine then becomes SAM-e (S-adenosylmethionine) — the universal methyl donor for DNA methylation, histone modification, neurotransmitter synthesis, and creatine production.
C677T polymorphism results in an alanine→valine substitution at position 677 of the MTHFR protein, reducing thermostability and enzyme activity. Heterozygous carriers show ~35% reduced activity. Homozygous (TT genotype) show 70% reduced activity. A1298C compound heterozygosity compounds the deficit further. Elevated homocysteine (>10 µmol/L) is the clinical marker — it indicates methionine synthesis is impaired and the cycle is backing up.
Unmetabolized folic acid (UMFA) from synthetic supplements competes with 5-MTHF at folate receptors and may inhibit dihydrofolate reductase, further impairing folate utilization in already-compromised individuals. Several studies have observed UMFA in plasma in populations with high fortified food intake, suggesting chronic partial blockade.
| Supplement | Dose | Purpose | Notes |
|---|---|---|---|
| L-Methylfolate (5-MTHF) | 400–1000mcg/day | Active folate — bypasses MTHFR | Replace all folic acid immediately |
| Methylcobalamin (B12) | 1000–5000mcg/day | Homocysteine conversion, methionine synthesis | Sublingual or injection for best absorption |
| TMG (Trimethylglycine) | 500–1000mg/day | Alternative methyl donor, homocysteine clearance | Works independent of MTHFR |
| Riboflavin (B2) | 10–100mg/day | MTHFR cofactor — increases enzyme activity in C677T carriers | Critical for homozygous TT individuals |
| Zinc | 15–30mg/day | Over 300 enzymatic reactions, methionine synthase cofactor | Take with food; don't exceed 40mg long-term |
| P5P (Pyridoxal-5-Phosphate) | 25–50mg/day | Active B6 — homocysteine clearance via transsulfuration | Active form of B6, bypasses another conversion step |
This is what makes methylation directly relevant to anyone on a weight loss journey, especially on tirzepatide or any GLP-1 medication. Brecka has documented case after case of people who were doing everything right — eating clean, exercising, taking medications — but couldn't lose weight or felt constantly exhausted. When methylation was fixed, everything else started working.
Here's why: methylation controls leptin signaling. Leptin is your satiety hormone. Poor methylation → impaired leptin receptor sensitivity → your brain doesn't register that you're full, even on tirzepatide. Fix the methylation, improve leptin sensitivity, and GLP-1 medications become dramatically more effective.
Methylation also controls: cortisol metabolism (poor methylation = chronically elevated stress hormones), estrogen clearance (especially relevant for women with estrogen dominance), and dopamine/serotonin production (which affects cravings and food noise directly).
Option 1: Order a genetic test. 23andMe includes MTHFR variants. Any standard genetics panel does too. Look for rs1801133 (C677T) and rs1801131 (A1298C).
Option 2: Test your homocysteine. Ask your doctor for a simple blood test. Normal is under 10 µmol/L. Above 12 is clinically elevated. Above 15 is high risk. Elevated homocysteine strongly suggests methylation impairment — even if you don't have MTHFR, something is blocking your cycle.
Option 3: Try switching to methylfolate and see how you feel. Many people notice improved energy, mood, and mental clarity within 2-4 weeks of switching. This is not a placebo — it's your biochemistry working the way it's supposed to.
Brecka's recommendation: Everyone should be on methylated B vitamins — not just MTHFR carriers. The methylated forms are more bioavailable for everyone. The only people who might need to go slow are those with COMT mutations (a different methylation gene), who can become over-methylated. Start low if you're unsure.
If you're on tirzepatide or any GLP-1, Brecka's methylation protocol is essentially foundational — you want it running before everything else. Here's why it stacks perfectly:
Tirzepatide reduces food intake and improves insulin sensitivity. But it works on signaling pathways that require proper methylation to function. Specifically: GLP-1 receptor expression itself is regulated partly by epigenetic methylation of the GLP1R gene. People with impaired methylation may have suboptimal receptor expression — meaning the drug has less to bind to. This could partially explain why some people respond dramatically to tirzepatide and others see minimal effect at the same dose.
Have a question about MTHFR, methylation, or how this interacts with your current protocol?
ASK JOB A QUESTION → DAILY BIOHACK NEWSLETTER →